Investors

Corporate Profile

At Bellerophon Therapeutics, we aim to transform the lives of people suffering from cardiopulmonary diseases by developing innovative therapies at the intersection of drugs and devices for these therapeutic areas and to do so while serving the best interests of our shareholders.

We are currently developing three product candidates under our INOpulse pro... more >

more >

Recent News

10/14/19

Summary Toggle Bellerophon to Present New Data from Cohort 1 of Ongoing Phase 2/3 Study of INOpulse® for Treatment of Pulmonary Hypertension Associated with Interstitial Lung Disease at CHEST 2019 Annual Meeting

Results to be Presented in Late-Breaking Abstract as an Oral Presentation Presentation Will Also be Published in the Highlights from CHEST Special Edition WARREN, N.J. , Oct. 14, 2019 (GLOBE NEWSWIRE) -- Bellerophon Therapeutics, Inc. (Nasdaq: BLPH) (“Bellerophon” or the “Company”), a
09/16/19

Summary Toggle Bellerophon Receives Orphan Drug Designation for Nitric Oxide in the Treatment of Idiopathic Pulmonary Fibrosis

WARREN, N.J. , Sept. 16, 2019 (GLOBE NEWSWIRE) -- Bellerophon Therapeutics, Inc. (Nasdaq: BLPH) (“Bellerophon” or the “Company”), a clinical-stage biotherapeutics company, announced today the U.S. Food and Drug Administration ( FDA ) has granted Orphan Drug Designation to nitric oxide for the
09/04/19

Summary Toggle Bellerophon to Present at the H.C. Wainwright 21st Annual Global Investment Conference

WARREN, N.J. , Sept. 04, 2019 (GLOBE NEWSWIRE) -- Bellerophon Therapeutics, Inc. (Nasdaq: BLPH) (“Bellerophon” or the “Company”), a clinical-stage biotherapeutics company, announced today that Fabian Tenenbaum , Chief Executive Officer, will present a corporate overview at the H.C.

more >

Stock Quote

more >

Bellerophon (: )

Data as of 10/15/19 8:49 PM EDT

more >

Presentations

Corporate Presentation

10/08/19

Corporate Presentation 1.5 MB
KOL Day Presentation

05/30/19

KOL Day Presentation 4 MB
ATS 2019 PH-ILD Poster

05/21/19

ATS 2019 PH-ILD Poster 310.5 KB
2019 ATS PH-ILD Presentation

05/21/19

2019 ATS PH-ILD Presentation 452.8 KB
2019 PVRI Poster – iNO DDI Study

02/02/19

2019 PVRI Poster – iNO DDI Study 339.9 KB
2019 PVRI Poster – Actigraphy in PH-PF

02/02/19

2019 PVRI Poster – Actigraphy in PH-PF 562 KB
Key Opinion Leader Lunch : Pulmonary Hypertension Associated with Interstitial Lung Disease (ILD) with Dr. Steve Nathan

08/09/17

Key Opinion Leader Lunch : Pulmonary Hypertension Associated with Interstitial Lung Disease (ILD) with Dr. Steve Nathan 4.5 MB
2017 ATS Poster - PH-IPF

05/23/17

2017 ATS Poster - PH-IPF 2.2 MB
2017 ATS Poster - PH-COPD

05/23/17

2017 ATS Poster - PH-COPD 3 MB
2017 ISHLT Poster

04/06/17

2017 ISHLT Poster 417.9 KB
2016 ATS Poster

05/19/16

2016 ATS Poster 971 KB
2015 PHPN Poster

09/19/15

2015 PHPN Poster 684.5 KB

Investors

Corporate Profile

Recent News

Stock Quote

Upcoming Events

Presentations

Corporate Presentation

KOL Day Presentation

ATS 2019 PH-ILD Poster

2019 ATS PH-ILD Presentation

2019 PVRI Poster – iNO DDI Study

2019 PVRI Poster – Actigraphy in PH-PF

Key Opinion Leader Lunch : Pulmonary Hypertension Associated with Interstitial Lung Disease (ILD) with Dr. Steve Nathan

2017 ATS Poster - PH-IPF

2017 ATS Poster - PH-COPD

2017 ISHLT Poster

2016 ATS Poster

2015 PHPN Poster